Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.43 |
| ▸ | P2RY12 | Q9H244 | 6/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.39 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.38 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.38 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18510956 | 1.00 | PRMT6 (0.43) | PRMT6P2RY12ADORA1BMPR1BLMNA | |
| SCHEMBL25808118 | 1.00 | PRMT6 (0.43) | PRMT6P2RY12ADORA1BMPR1BLMNA | |
| SCHEMBL20248724 | 1.00 | PRMT6 (0.43) | PRMT6P2RY12ADORA1BMPR1BLMNA | |
| SCHEMBL18521428 | 0.95 | ADORA1 (0.43) | PRMT6P2RY12ADORA1 | |
| SCHEMBL19145880 | 0.94 | PRMT6 (0.43) | PRMT6P2RY12ADORA1BMPR1BLMNA | |
| SCHEMBL26435560 | 0.93 | PRMT6 (0.41) | PRMT6P2RY12ADORA1 | |
| SCHEMBL26554337 | 0.92 | PRMT6 (0.45) | PRMT6P2RY12ADORA1BMPR1BP2RY2 | |
| SCHEMBL20248713 | 0.92 | PRMT6 (0.45) | PRMT6P2RY12ADORA1BMPR1BP2RY2 | |
| SCHEMBL25679990 | 0.91 | PRMT6 (0.45) | PRMT6P2RY12ADORA1BMPR1BP2RY2 | |
| SCHEMBL30012528 | 0.91 | PRMT6 (0.40) | PRMT6P2RY12ADORA1BMPR1BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | US | disclosed |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | ALIGOS THERAPEUTICS, INC. (US) | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365970-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | PRMT6 1699/4885P2RY12 3542/4885ADORA1 1303/4885 |
| US-20230332153-A1 | Modified Short Interfering Nucleic Acid (siNA) Molecules and Uses Thereof | NSUN2, SNRPA, SNRPF | PRMT6 1699/4885P2RY12 3542/4885ADORA1 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.